Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells

AIDS

Volumn 16, Issue 2, 2002, Pages 171-180

  Larsson, Marie ^a   Wilkens, David T ^b   Fonteneau, Jean François ^a   Beadle, Thomas J ^c   Merritt, Melissa J ^c   Kost, Rhonda G ^c   Haslett, Patrick A J ^a   Cu Uvin, Susan ^d   Bhardwaj, Nina ^a   Nixon, Douglas F ^b   Shacklett, Barbara L ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^c AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Cytotoxic T lymphocytes; Dendritic cells; HAART

Indexed keywords

ANTIRETROVIRUS AGENT; CD8 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; INTERLEUKIN 4; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BLOOD; CELL MATURATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DENDRITIC CELL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; LYMPHOCYTE COUNT; MALE; MEMORY CELL; MONOCYTE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINIA VIRUS;

ADULT; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FALSE POSITIVE REACTIONS; FEMALE; FLOW CYTOMETRY; FREEZING; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MONOCYTES; PHOSPHOPROTEINS; RECOMBINATION, GENETIC; TRANS-ACTIVATORS; VACCINIA VIRUS; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 0037169175     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200201250-00005     Document Type: Article

References (65)

1. DC-SIGN: A guide to some mysteries of dendritic cells
2. Dendritic cells and the control of immunity
3. The immunological synapse: A molecular machine controlling T cell activation
4. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses
5. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
6. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products
7. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures
8. Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses
9. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells
10. High level IL-12 production by murine dendritic cells: Upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10
11. Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2
12. Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes
13. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques
14. Cutaneous dendritic cells promote replication of immunodeficiency viruses
15. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells
16. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals
17. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers
18. Counting antigen-specific CD8 T cells: A re-evaluation of bystander activation during viral infection
19. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors
20. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells
21. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy
22. Induction of maturation of human blood dendritic cell precursors by measles virus is associated with immunosuppression
23. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA
24. Vaccinia virus inhibits the maturation of human dendritic cells: A novel mechanism of immune evasion
25. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells
26. The distinct surface of human blood dendritic cells, as observed after an improved isolation method
27. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T- cell receptor usage of pp65-specific CTL
28. Recognition of influenza A matrix protein by HLA-A2-restricted cytotoxic T lymphocytes. Use of analogues to orientate the matrix peptide in the HLA-A2 binding site
29. Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes
30. Phenotypic analysis of antigen-specific T lymphocytes
31. Prolonged CD8+ T-cell expansions after adoptive transfer of syngeneic lymphocytes between HIV-discordant identical twins
32. Qualitative differences between naive and memory T cells make a major contribution to the more rapid and efficient memory CD8+ T cell response
33. Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton
34. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses
35. Differential presentation of the same MHC class I epitopes by fibroblasts and dendritic cells
36. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL
37. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes
38. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability
39. Identification of subdominant cytotoxic T lymphocyte epitopes encoded by autologous HIV type 1 sequences, using dendritic cell stimulation and computer-driven algorithm
40. Superdominance among immunodominant H-2Kb-restricted epitopes and reversal by dendritic cell-mediated antigen delivery
41. Antigen presentation by dendritic cells focuses T cell responses against immunodominant peptides: Studies in the hen egg-white lysozyme (HEL) model
42. Immunotherapy of cancer with dendritic-cell-based vaccines
43. HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines
44. Dendritic cells are potent antigen-presenting cells for in vitro induction of primary human CD4+ T-cell lines specific for HIV gp120
45. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1- biasing cytokines IL-12 and IFN-alpha
46. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro
47. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
48. Induction of primary human CD8+ T lymphocyte responses in vitro using dendritic cells
49. A method for the production of cryopreserved aliquots of antigen- preloaded, mature dendritic cells ready for clinical use
50. Freezing of dendritic cells, generated from cryopreserved leukaphereses, does not influence their ability to induce antigen-specific immune responses or functionally react to maturation stimuli
51. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease
52. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
53. Progressive loss of IL-2-expandable HIV-1-specific cytotoxic T lymphocytes during asymptomatic HIV infection
54. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
55. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy
56. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART)
57. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
58. Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children
59. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
60. Cytomegalovirus (CMV)-speciflc T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load
61. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
62. Transplantation-related lymphoproliferative disorder: A model for human immunodeficiency virus-related lymphomas
63. Hairy leukoplakia: An unusual combination of transforming and permissive Epstein-Barr virus infections
64. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
65. Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells